Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature

Asiyeh Amouei¹, Nesa Daeian¹, Seyyedeh Sana Khezria¹, Ava Mansouri¹, Molouk Hadjibabaie²

¹Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
²Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Corresponding Author: Ava Mansouri, Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
Tel: +98 21 88814157
Email: ava_mansouri_j@yahoo.com

Received: 31, Dec, 2019
Accepted: 17, May, 2020

ABSTRACT
Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survivals.

Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keywords in PubMed, Web of science, Scopus, Ovid, ProQuest, Science direct and Google scholar for English studies. We also investigated the aforementioned terms’ correspondence in Magiran, Scientific information database (SID) and Google scholar for Persian articles.

Results: 25 studies were selected for final analysis. Reported hematologic responses from adult studies ranged 86-99% and major molecular responses were estimated in 38.84% of our patients within 12 months of treatment. The most frequent reported adverse drug reactions (ADRs) were edema (n=5 studies, 100%) and fatigue and nausea (n=4 studies, 80%); ADR per capita ratio was 1.46. Only one study informed ADRs in pediatrics demonstrating 93% of patients experienced ADRs after receiving imatinib.

Most of the Studies (n=4, 67% from 7 studies) considered BCR/ABL point mutation as main reason of imatinib resistance. Drug-binding site and P-loop regions were two common sites for BCR/ABL point mutation.

Conclusion: Imatinib as the first line treatment for CML has been associated with proper and durable responses in Iranian adults and children CML patients. Moreover, Imatinib life-threatening adverse effects were reported uncommon. Various responses to modified regimens have been reported in resistant patients; therefore, individualized treatment based on mutation type could be recommended.

Keywords: Imatinib mesylate; Treatment outcome; Antineoplastic agent resistance; Chronic myeloid leukemia; Adverse drug event

INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic cells that is identified by Philadelphia chromosome as a result of reciprocal translocation between chromosomes 9 and 22, t (9; 22) (q34; q11)¹ which leads to BCR/ABL chimeric gene². The BCR/ABL gene encodes an oncprotein, a constitutive active tyrosine kinase, which enhances cell proliferation and apoptosis inhibition by stimulating several signaling pathways, leading to overgrowth of leukemic cells and CML³,⁴.

Imatinib Mesylate is the first tyrosine kinase inhibitor (TKI) that was introduced in 2001 for clinical practice in CML patients⁵. It induces apoptosis and inhibits proliferation in BCR/ABL-expressing cells through competitive blockage of ATP binding to BCR/ABL tyrosine kinase⁶. Imatinib is the first line treatment in CML patients⁷, which leads to proper responses as
82% complete cytogenetic response (CCyR), overall survival (OS) rate of 86%, event-free survival (EFS) rate of 81% and 93% transformation-free survival at 7 years. The rate of imatinib resistance is estimated 4% per year from a 5-year follow up evaluation, which is higher in advanced disease stages. For instance, in Accelerated Phase-CML (AP-CML), imatinib resistance is 45% and 75% after 2 and 4 years of imatinib therapy, respectively. Second-generation of TKIs, dasatinib (in 2006) and nilotinib (in 2007) initially were developed for imatinib resistant and/or intolerant patients. Following increased response rate and decreased disease progression, FDA approved new TKIs as frontline CML therapy in 2010. Despite the superiority of these new TKIs in some aspects, review of the literatures indicates that imatinib still has an acceptable efficacy and safety profile in the treatment of CML. In addition, the price of the Second-generation of TKIs is extremely higher than imatinib. Therefore, imatinib still is the first line treatment of CML in many Asian countries as well as Iran. Since regional differences in biologic, environment and socioeconomic factors, the type and source of consumed imatinib and even patients’ genetic background impacts on the treatment outcomes, it is essential for each region or country to precisely evaluate the rationality of the practice based on their population studies. Therefore, we decided to review the available evidence from Iran to assess if it supports imatinib therapy as first line treatment in Iranian CML patients. This paper reviews all available studies on imatinib efficacy, safety and resistance in Iranian children and adult patients.

MATERIALS AND METHODS
Data Sources and Searched Terms
In order to review available literature on imatinib efficacy, safety and resistance in Iranian CML patients, we accomplished a systematic search using different databases and publishers search engines. We searched PubMed, Web of science, Scopus, Ovid, ProQuest, Science direct and Google scholar for English studies. Likewise, Magiran, Scientific information database (SID) and Google scholar were investigated for Persian articles.

We performed our search using (“imatinib” OR “gleevec” OR “glivec” OR “imatinib as MeSH”) AND (“Iran” OR “Iranian” OR “I.R.Iran”) AND (“Iran” OR “Iranian” OR “I.R.Iran”) and their corresponding Persian equivalents within the title, abstract, keywords or MeSH based on search engines characteristics. Limitations and filters were supposed to be applied only if we encountered with various irrelevant results. Afterward, we also manually searched references within relevant articles with the intention to avoid omitting any proper study. The search time span was up to October 2019.

Inclusion and Exclusion Criteria
We included all original, population based studies on Iranian adults and children CML patients with any extractable information about imatinib efficacy and/or adverse effects and/or resistance; i.e., clinical trials, longitudinal, cohort, cross-sectional, case-series and case-control studies. Hence, letters, case reports, conference papers, organizational reports, opinions or editorial papers were eliminated. Furthermore, case reports that described new imatinib adverse events were remained.

We also excluded publications which contained studies on cell lines and animal models likewise studies that investigated outcomes of gastrointestinal stromal tumor (GIST) patients.

Selecting Studies
We imported all search results to Endnote X8 library. After removing duplicated studies, two authors independently reviewed the remained articles through titles and abstracts screening and irrelevant studies were eliminated according to aforementioned inclusion and exclusion criteria. Full texts were assessed in case the title or abstract were not informative enough.
Information extraction and Reporting

We extracted and summarized the applicable data, which was reported in the most recruited articles in four Tables. These data were summarized and completed for each article based on the listed characteristics in 4 Tables:

Table 1:
- Study characteristics [Authors’ name/publication year, time of research, study design, comparison arms]
- Patients characteristics [patient’s age group, sex, range of age]
- Disease and treatment characteristics [disease phase, treatments before imatinib therapy, imatinib type and initial dose, duration of imatinib therapy]
- Follow-up characteristics [treatment modification and its cause, response after treatment modification, follow up duration]

Table 2:
- Efficacy profiles [types of response (hematologic, molecular, cytogenetic and none), OS, progression-free survival (PFS), frequency of disease progression and its reasons, mortality rate and its causes]

Table 3:
- Resistance characteristics [type of resistance, disease phase in mutated patients, detection methods, name of evaluated genes, frequency of mutation site in BCR/ABL kinase domain, percentage of gene mutation frequency (number of gene mutation/total detected mutation*100), T315I mutation assessment, percentage of patients’ mutation frequency (number of mutated patients/all resistant patients *100)]

Table 4:
- Adverse drug reactions (ADRs) [frequency of patients with ADRs (number of patients who experienced ADRs/total patients who received imatinib), severity of ADRs (based on Common Terminology Criteria for Adverse Events (CTCAE) as follow: Grades 1 and 2 are mild and moderate reactions, respectively which do not need intensive interventions. Grades 3 and 4 are severe AEs, which demand medical interventions. In grade 3, adverse events lead to medical therapy or hospitalization or prolongation of hospitalization and in grade 4, life-threatening events require immediate significant therapeutic interventions.)]

We also reported the ADRs per capita which is estimated by dividing total number of ADRs occurrence to total number of included patients.
Table 1: Study, patients, disease, treatment and follow up characteristics of the reviewed articles

| Authors / Years | Study, patients, disease, treatment and follow up characteristics | Follow-up characteristics |
|----------------|---------------------------------------------------------------|---------------------------|
| Authors / Years | Study, patients, disease, treatment and follow up characteristics | Follow-up characteristics |
|----------------|---------------------------------------------------------------|---------------------------|
| Bahous Gr, et al. /2009 (20) | Patients characteristics: Age group: child, M (6), F (8); Age range: 2.5-14 | IM dose escalation to 320 (12%) |
| Hamidi eh AA, et al. /2013 (40) | Patients characteristics: Age group: child, M (6), F (13); Age range: 2-16 | 12 |
| Navidi GR, et al. /2005 (17) | Patients characteristics: Age group: adult, M (17); Age range: 14-83 | IM dose escalation to 600 (NA) |
| Razmk hah F, et al. /2010 (31) | Patients characteristics: Age group: adult, M (16); Age range: 47-143 | IM dose escalation to 800 (NA) |
| Valizadeh N /2011 (25) | Patients characteristics: Age group: adult, M (1); Age range: 28-NA | IM dose escalation to 800 (NA) |
| Jalaei hoo H, et al. /2011 (37) | Patients characteristics: Age group: adult, F (34), M (26); Age range: 13-80 | IM dose escalation to 800 (NA) |
| Mosh feghi K, et al. /2013 (19) | Patients characteristics: Age group: adult, F (34), M (60); Age range: 40.9±14.5 | IM dose escalation to 600 (NA) |
| Moza heb Z, et al. /2020 | Patients characteristics: Age group: adult, F (34), M (48); Age range: 48-AP | IM dose escalation to 600-800 mg (10) |

**Note:**
- IM: Imatinib
- CP: CP (CPH)
- HU: HU (NA)
- INF: INF (NA)
- AP: AP (NA)
- Gener ic imatin ib: Gener ic imatin ib
- IM dose reduction to 100-300 mg (5)
- IM interruption (9)
- IM dose escalation (10)
- Grade 3 or 4 neutropenia and thrombocytopenia noted in two pts on high-dose therapy/improved condition after discontinuation of therapy for two weeks
- No CHR after 3 months or no MCyR after 12 months and at least if the pts relapsed within 3 months after attaining CHR
- Absence of appropriate treatment response
- Inadequate efficacy or intolerability
- Unresponsive After a median follow-up of 36 months from dose escalation, Median 44 (8-115)
| Authors / Years | Age group | Sex (no.) | Age (range) | Patient s’ disease phase on IM therapy (no.) | Treatment before IM therapy (no.) | Duration of IM therapy (range) | IM brand | Initial dose | Treatment modification (no.) | Causes of treatment modification | Response after treatment modification | Follow up (months) |
|----------------|-----------|-----------|-------------|-------------------------------------------|----------------------------------|---------------------------------|----------|-------------|--------------------------------|-------------------------------|----------------------------------|------------------|
| 14 (26) Golabchifar AA, et al./20 | Adult | F (25) | 32 | BP (2) | IM 1st line (47) | (12-36) | NA | NA | NA | nil or severe toxicity | 70% of them remained alive | NA |
| 15 (22) Mohajeri E, et al./20 | Adult | F (17) | 44 | CP (36) | NA | NA | Imatinib & Imatinib by Osveh | 400 | NA | NA | NA | NA |
| 15 (27) Salamizand H, et al./20 | Adult | F (29) | 47.9 | CP (59) | IM 1st line | Mean±SD | 44.16±23.16 | Gleevec | 400 | IM dose escalation to 600 mg (14) | -Suboptimal response and failure to IM | NA | NA |
| 15 (39) Payan Mohajer M, et al./20 | Adult | M (27) | 45.7 | CP (54) | IM 1st line | 6 | Indian brand | 400 | NA | NA | NA | NA |
| 15 (41) Payan Mohajer M, et al./20 | Adult | F (42) | 47.5 | CP (85) | IM 1st line | NA | NA | 400 | NA | NA | NA | NA |
| 15 (30) Rejali L, et al./20 | Adult | F (14) | 46 | CP (NA) | NA | 0 to > 61 | NA | 400 | -IM dose Escalation to 500 or 600 mg -Nilotinib or Dasatinib | -IM resistance -Failure MR (25; 63.2) -Warning category (4; 10.2) | NA | NA |
| Authors / Years | Age group | Sex (no.) | Age (range) | Disease and treatment characteristics | Patient s’ disease phase on IM (no.) | Treatment before IM therapy (no.) | IM brand | Initial dose | Follow-up characteristics |
|----------------|-----------|-----------|-------------|----------------------------------------|--------------------------------------|-----------------------------------|----------|--------------|--------------------------|
| Rostami G, et al./2015 (38) | Adult | F (15) | Median 50 (32-70) | | | | | | | -Optimal response (10; 26.3) |
| Abbasian S, et al./2015 (42) | Adult | F (20) | Median 40 (15-46) | | | | | | | -MRR (10;45.45) |
| Chahardoul i B, et al./2013 (23) | Adult | F (23) | Median 44 (12-77) | | | | | | | -Dead, two of three mutated pts |
| Chahardoul i B, et al./2013 (24) | Adult | F (43) | Median 42 (10-83) | | | | | | | -Increased BCR/ABL copy numbers to 86.6 and peak of T315I mutation to 60% and finally death (1) -Relapse 3 months after HSCT and death (1) |
| Solali S, et al./2013 (29) | NA | NA | NA | | | | | | | -Absence of treatment response |
| Nekohesh L, et al./2019 (36) | Adult | F (119) | Median 41.3 (18-84) | | | | | | | -Suboptimal response |
| Total | | | | | | | | | | Median 34.8 (3-845) |
| Authors / Years | Patients characteristics | Disease and treatment characteristics | Follow-up characteristics |
|----------------|--------------------------|----------------------------------------|--------------------------|
| Payan deh M, et al./2018 (35) | | | |
| Adults (no.) | Age (range) | Patient s' disease phase on IM (no.)* | Treatment before IM therapy (no.) | IM duration therapy (range) | IM therapy (no.) | Initial dose | Treatment modification (no.) | Causes of treatment modification | Response after treatment modification | Follow up (months) |
| Adult | F (36) | M | 41 (21-80) | CP (60) | Median 4 (1-10) | NA | 400 | NA | NA | NA |
| Safaei A, et al./2018 (28) | | | |
| Adults and pediatrics (no.) | Age (range) | Patient s' disease phase on IM (no.)* | Treatment before IM therapy (no.) | IM duration therapy (range) | IM therapy (no.) | Initial dose | Treatment modification (no.) | Causes of treatment modification | Response after treatment modification | Follow up (months) |
| Adult | Mean (44) | Mean (4-90) | CP (81.3%) | NA | NA | NA | NA | NA | NA | NA |
| Vatanmakian M, et al./2019 (32) | | | |
| Adult (no.) | Age (range) | Patient s' disease phase on IM (no.)* | Treatment before IM therapy (no.) | IM duration therapy (range) | IM therapy (no.) | Initial dose | Treatment modification (no.) | Causes of treatment modification | Response after treatment modification | Follow up (months) |
| Adult | F (11) | M | 49 (21-75) | CP (9) | NA | NA | 200-400 for CP | NA | NA | NA |
| Rostami G, et al./2017 (33) | | | |
| Adult (no.) | Age (range) | Patient s' disease phase on IM (no.)* | Treatment before IM therapy (no.) | IM duration therapy (range) | IM therapy (no.) | Initial dose | Treatment modification (no.) | Causes of treatment modification | Response after treatment modification | Follow up (months) |
| Adult | F (28) | M | 49 (17-81) | CP (60) | Median 48 (3-142) | NA | 400 or 800 | NA | NA | NA |
| Chahardoul i B, et al./2019 (18) | | | |
| Adult (no.) | Age (range) | Patient s' disease phase on IM (no.)* | Treatment before IM therapy (no.) | IM duration therapy (range) | IM therapy (no.) | Initial dose | Treatment modification (no.) | Causes of treatment modification | Response after treatment modification | Follow up (months) |
| Adult | F (38%) | M | 21-82 | NA | NA | 18-60 | NA | NA | NA | NA |

*aPatients excluded if they had received treatment with HU, INF-α or cytarabine and any other investigational agent within seven, 14 and 28 days, respectively before starting the study treatment. bIt means that the patient should take the drug until the disease progressed or relapsed. cThe dosage of Imatinib was adjusted according to non-hematological and hematological toxicities. dA lot of information is missed. pt(s): patient(s). ¥ total numbers of patient equal to all patients on imatinib therapy, = imatinib dosing for adult mg/day and for children mg/m2/day. P Number of patients/all included patients*100 I Number of patients/number of mutated patients*100. NA; not available or not applicable, IM; imatinib mesylate, HSCT; Hematopoietic stem cell transplantation, CML; chronic myeloid leukemia, CP; chronic phase, AP; accelerated phase, BP; blastic phase, HU; hydroxyurea, INF; interferon, CHR; complete hematologic response, MCyR; Major cytogenetic response, MR; molecular response, MMR; major molecular response.
Table 2: Imatinib efficacy in Iranian CML patients

| Authors/year | Response | Mortality % (Cause) | Progression to AP or BP no. (%) | Overall Survival (%) | Time to event end points (%) |
|--------------|----------|---------------------|---------------------------------|----------------------|-----------------------------|
| Jalaeikho H, et al./2011 (36) | 413 (99) | NA | NA | 7.4 (relapse, MI and car accident) | 46 (11) | 6-year OS (89) |
| | | | | | 6-year EFS (83) | |
| Mozahed Z, et al./2014 (26) | 56 (94) | MR (28.46,8) | NA | 6.67 (progressive disease) | 8 (13.4) | 4-year OS (85) |
| | | | | | 44-month EFS (65) | |
| Razmkhah F, et al./2010 (31) | 27 (90) | NA | NA | NA | NA | NA |
| Payandeh M, et al./2015 (71) | 63 (90) | NA | NA | NA | 5-year OS (90.5) | |
| | | | | | NA | |
| Moshfeghi K, et al./2013 (19) | Iranian brand: 86% | Indian brand: 46.5% | Indian brand: 44.2% | NA | NA | NA |
| Golabchifar AA, et al./2014 (21) | NA | MMR (31.51.7) | CCyR (8.13.3) | NA | NA | NA |
| Salamizand H, et al./2015 (27) | 63 (90) | NA | CyR (49.70) | NA | NA | NA |
| Nekoohesh L, et al./2019 (35) | NA | MMR (15.38.25.18, 44.1.52.97.60.75) at 3, 6, 12, 18, and 24 months | EMR (40%) | NA | NA | NA |
| | | | | | NA | |
| Payandeh M, et al./2018 (34) | NA | MMR (15.38.25.18, 44.1.52.97.60.75) at 3, 6, 12, 18, and 24 months | EMR (40%) | NA | NA | NA |
| Vatanmakanian M, et al./2019 (32) | CHR (88.8%) in CP pts at 6 months; (60% in AP pts) at 11 months; (50% in BP pts) | MMR (15 out of 25 pts with e13a2 transcript type; 30 out of 35 pts with e14a2 type) up to 24 months | NA | NA | NA | NA |
| | | | | | NA | |
| Rostami G, et al./2017 (33) | NA | MMR (15 out of 25 pts with e13a2 transcript type; 30 out of 35 pts with e14a2 type) up to 24 months | CCR (22 of the remaining 30 pts with e14a2 transcripts; five of the remaining 15 pts with e13a2 transcripts) up to 12 months | NA | NA | NA |
| | | | | | NA | |
| Safaei A, et al./2018 (28) | NA | MMR (72.5% of pts without ACA) | CCyR (22 of the remaining 30 pts with e14a2 transcripts; five of the remaining 15 pts with e13a2 transcripts) up to 12 months | NA | NA | NA |
| Bahoush Gr, et al./2009 (20) | Early CP: 7 (100) | MMR (72.5% of pts without ACA) | CCyR (22 of the remaining 30 pts with e14a2 transcripts; five of the remaining 15 pts with e13a2 transcripts) up to 12 months | NA | NA | NA |
| | Late CP: 6 (85.7) | | | NA | NA | NA |
| Hamidieh AA, et al./2013 (39) | 11 (57.9) | NA | NA | NA | NA | NA |

*They are reported based on various BCR-ABL1 categories at different months. †Cum survival of 76 patients was calculated in this article: survival of patients with ACA; 49.7±11.1 months and survival of those without ACA; 77.3±3.1 months. pt(s): patient(s); HR: hematologic response; CHR: complete hematologic response; NA: not available; CP: chronic phase; AP: accelerated phase; BP: blastic phase; MR: molecular response; EMR: early molecular response; MMR: major molecular response; DMR: deep molecular response; NMR: no molecular response; CMR: complete molecular response; ACA; additional cytogenetic aberrations, PMR: partial molecular response; CyR: cytogenetic response, CCyR: complete cytogenetic response, PCyR: partial cytogenetic response, CCR: complete cytogenetic response equivalence, MI: myocardial infarction, OS: overall survival, EFS: event free survival, DFS: progression free survival, DFS: disease free survival.
Table 3. Imatinib resistance characteristics in Iranian CML patients

| Author(s) /Year | Type of resistance | Phases in mutated patients (no.) | Detection methods | Name of evaluated genes | T315I mutation assessment | Frequency of mutation site in BCR/ABL domain (%$^*$) >10% | Gene mutation frequency(%$^*$) | Patients mutation frequency %$^*$ |
|-----------------|--------------------|----------------------------------|-------------------|-------------------------|--------------------------|--------------------------------------------------------|-----------------------------|-----------------------------|
| Rejali L, et al./2015 (30)* | Secondary | AP (3) CP (1) | PCR-RFLP, DS | G250E L384M Y253H V379I | NA | P-loop (75) Between C-domain and A-loop (25). | G250E (25) L384M (25) Y253H (25) V379I (25) | 10.25 |
| Rostami G, et al./2015 (38) | Primary Secondary | CP (3) | DS | E355G G398R | No mutation was observed | C-domain (66.66) A-loop (33.33) | E355G (66.66) G398R (33.33) | 13.63 |
| Abbassian S, et al./2015 (42) | NA | NA | Real time-PCR | SIRT1 expression | NA | NA | NA | NA |
| Chahardouli B, et al./2013 (23) | NA | AP (2) BP (2) | ASO-RT-PCR, BDS | T315I | Mutation was observed | Drug-binding site | NA | 7 |
| Chahardouli B, et al./2013 (24) | NA | CP (21) AP (3) BP (8) | BDS | G250E, T315I M244V, F359C E255K, M351T F359V, E459G Y253H, E255V D276N, E279A F317L, E355G L387M, L387V H396R, S438C E453A | Mutation was observed | Drug-binding site | G250E (14.7) T315I (11.8) | 29.1 |
| Solali S, et al./2013 (29) | NA | NA | SYBER-Green Real-time RT-PCR | hOCT1 MDR1 | NA | NA | NA | NA |
| Chahardouli B, et al./2019 (18) | NA | NA | Real-time PCR | STAT3 expression | NA | NA | NA | NA |

*$^*$The reported data in this article were ambiguous and confusing. £ number of gene mutations/total mutations*$^*$100, I number of mutated patients/total resistant patients*$^*$100, NA; not available or not applicable, AP; accelerated phase, BP; blastic phase, CP; chronic phase, PCR; polymerase chain reaction, RFLP; restriction fragment length polymorphism, RT; reverse transcription, ASO; allele-specific oligonucleotide, DS; direct sequencing, BDS; bidirectional sequencing, hOCT1; human organic cation transporter, MDR1; multi-drug resistance 1, P-loop; phosphate-binding loop, A-loop; activation loop, C-terminal; carboxyl-terminal, C-domain; catalytic domain
Table 4: Frequency of imatinib adverse events

| Adverse events                  | Grade 1 or 2-% | Grade 3 or 4-% |
|---------------------------------|----------------|----------------|
| Edema‡                         | 1 (16), 56.4 (40), 62.7 (21), 55.6 (22), 42.8 (12), 22.3 (20) | 7.3 (23), 7.4 (22) |
| Nausea                         | 21.3 (40), 42.1 (21), 20.4 (22), 42.8 (12), 27.8 (20) | 3.3 (40), 5.6 (22), 7.1 (12) |
| Vomiting                       | 1.7 (40), 14.8 (22), 42.8 (12) | 5.6 (22), 7.1 (12) |
| Myalgia                        | 23 (40), 48.2 (22), 5.3 (14), 28.6 (12), 22.3 (20) | 13 (22) |
| Musculoskeletal pain           | 37 (40), 57.1 (12) | 3.6 (40) |
| Skin rash                      | 28.3 (40), 5.3 (14), 16.7 (20) | 6.6 (40) |
| Abdominal pain                 | 39 (21), 18.5 (22), 21.4 (12), 33.4 (20) | 9.2 (40) |
| Fatigue                        | 43 (40), 43.8 (21), 30.5 (20) | - |
| Thrombocytopenia               | 1.4 (16), 13.3 (40), 10.45 (21) | 3.3 (40) |
| Diarrhea                       | 0.5 (16), 11.1 (22), 5.5 (20) | - |
| Arthralgia                     | 10 (40), 50 (22), 5.3 (14), 28.6 (12) | 11.1 (22) |
| Neutropenia                    | 11.67 (40), 9.3 (21) | 3.3 (40) |
| Ostealgia                      | 35.2 (22), 5.3 (14) | 13 (22) |
| Muscle cramps                  | 37 (22), 21.4 (12) | 20.4 (22) |
| Infection                      | 5 (40), 16.7 (22) | 3.7 (22) |
| Weight gain                    | 18.5 (22), 57.1 (12) | - |
| Headache                       | 39.5 (21), 25 (20) | - |
| Hemorrhagic events             | 17.6 (40), 3.7 (22) | - |
| Anemia                         | 66.7 (40) | 3.3 (40) |
| Depression                     | 24 (22) | 5.6 (22) |
| Insomnia                       | 22.2 (22) | 14.8 (22) |
| Weight loss                    | 20.4 (22) | 1.85 (22) |
| Constipation                   | 18.5 (22) | 3.7 (22) |
| Cough                          | 18.5 (22) | 1.65 (22) |
| Fever                          | 14.8 (22) | 3.7 (22) |
| Pancytopenia                   | 14.3 (12) | 14.3 (12) |
| Pruritus                       | 11.7 (40) | 10 (40) |
| Liver toxicity                 | 9.6 (40) | 1.9 (40) |
| Dizziness                      | 21.8 (40) | - |
| Dyspnea                        | 14.3 (12) | - |
| Red eye                        | 5 (40) | - |
| Urinary retention              | 1.85 (22) | - |
| Leukopenia                     | 1.2 (16) | - |

‡ including peripheral, periorbital, superficial edema and fluid retention, β sinusitis and throat infection, ¥ including bleeding tendency and subconjunctival hemorrhage
DISCUSSION
We found that Iranian studies assessed imatinib effectiveness more than its safety and resistance. They were mostly performed in adults rather than children. Estimated median age of CML patients from European population-based registries ranged between 57-60 years, while it also stated that age of patients in clinical trials were 10 years lower. The age of participants in our review ranged between 2 to 90 years. According to the studies reporting age, the age average and median of patients described 46.3 and 45.76, respectively, which are close to what Höglund et al. stated about clinical trials.
In our review article, males were recruited 1.21 times more than females which is the same as what was reported previously (about 1.2-1.7). These studies frequently recruited CP-CML patients and imatinib was often used as first-line therapy at dose of 400 mg. Despite existence discrepancies within reviewed studies regarding study design, participants, comparator groups, reporting different outcome measures, efficacy of imatinib was not noted inferior than comparator groups (e.g. HSCT) and developed acceptable responses in both adults and pediatrics. However, it should be considered that no study compared imatinib outcome to new TKIs generation such as nilotinib. Moreover, induced imatinib ADRs were often mild to moderate, and no death reported due to toxic effects.

Disease and treatment characteristics
Although imatinib is the drug of choice in CP of CML, other drugs such as interferon-α (IFN-α) and hydroxyurea (HU) have been prescribed for CML treatment. Two studies, both by Chahardouli et al., reported the chemotherapy regimen before imatinib resistance occurrence. He reported that 41.7% and 22.7% patients were received HU plus IFN-α; however, imatinib was as the most prescribed first-line therapy as expected. This is also confirmed by studies other than our review article that about 20% of cases started drugs other than imatinib at first then they switched to imatinib after losing their response to the primary regimen.

Imatinib resistance frequency is clinically important in guideline development, health regulatory and decision making. Despite the fact, only Rejali et al. evaluated the frequency of imatinib resistance cases in Iranian CML population (39 resistant cases from 135 CML patients; 29%).

Effectiveness and Safety of imatinib in adults
In 2010, FDA announced that second generation of TKIs (dasatinib and nilotinib) is suitable as choice of CML therapy due to their superior cost-effectiveness. Consequently since then, they became first-line treatment in some developed countries. However, from a different viewpoint by expiring Gleevec® patent in 2016 and releasing low-cost generic form of imatinib, it seems that imatinib also could be cost-effective and prescribed as first choice of treatment for many patients. In Iran, the generic forms of imatinib are available. In comparison, nilotinib, the only existing second TKI generation in Iran, is accessible only as its original brand (Tasigna) that is much more expensive than generic imatinib despite being insured. Therefore, in Iran, like some other countries mostly developing ones imatinib is the drug of choice at the beginning of CML treatment based on Iran standard protocol. Accordingly, in our studies, imatinib was mostly used as the first-line treatment (in some rare cases HU plus IFN-α were the 1st line treatment).

Also, we found Indian generic version of imatinib was mostly used in our studies. There are several reasons which can lead to this practice; 1) highly cost of Gleevec® which can be due to its high price and lack of national insurance coverage; 2) the physician beliefs in better quality of Indian generic vs. Iranian generic forms and 3) Inaccessibility of Iranian generic version of imatinib due to absence of their production inside the country during study periods (Iranian generic released in 2010 when the most studies had begun).

Considering the CML different phases, imatinib was effective in all phases in our included studies which are in accordance with the review by Pulsipher et al.
Imatinib efficacy in our included studies was reported by different response and outcome measures. The range for hematologic responses in our review was near to other adult studies. Only Moshfeghi et al. reported hematologic responses less than other studies (86%). This can be explained by higher age of recruited patients since Sanchez-Guijo et al. confirmed that aging is associated with decrease in response. Mean of MMR from our patients (38.84%) was better than what was reported in a systematic review (33.6%) in which 8 clinical studies were reviewed and compared relative efficacy of three TKIs.

The extracted OS and EFS from the current review proved durable imatinib consequence and were in accordance to IRIS trial. Although Mozaheb et al. reported lower rate for outcomes (65% for both OS and EFS), the difference could be due to the disease phase of Mozaheb et al. study population (patients were in AP and BP) based on previously lower PFS and OS rate of patients in AP-CML reported by Talpaz et al.

One of our included studies compared the effect of imatinib and hematopoietic stem cells transplantation (HSCT) by different measures; the percentage of BCR-ABL gene expression in several time points. The results showed that extent of gene expression after 8 months treatment statically was not different in both groups. Therefore, it was suggested that invasive techniques (HSCT) is better to be replaced with non-invasive methods (imatinib) at least in early disease phase.

Disease progression to AP or BP was reported to be the main cause of death in CML patients. Although in our studies there was a slightly higher percentage of progression (11, 11.5% vs. 7), our mortality rate was lower (7% vs. 10-12%). The reason could not be clarified based on the reported findings in our studies. According to Rostami et al. study, BCR-ABL1 transcript types can affect patients’ response to imatinib. Patients with e14a2 transcript had lower probability of recurrence, better and faster response to imatinib. Fifteen out of 25 patients with e13a2 transcript type and 30 out of 35 patients with e14a2 type achieved MMR up to 24 months.

ADRs due to imatinib therapy in CML patients have been reported to be mild to moderate and are mostly manageable. In contrast with IRIS study in which 30% of patients experienced severe ADRs, the results of our studies supported acceptable safety profile of imatinib in Iranian CML patients according to its frequency and severity.

The calculated ADR per capita in our study (1.5) was lower than other studies (1.6 and 2.7). In addition, the proportion of mild and moderate to severe and life threatening ADRs was higher compared to the only study in which its indicator was applicable (7.2 vs. 5.3). Hence, it seems imatinib induced less and lighter ADRs in Iranian patients.

In our included studies, as expected, the most common ADRs were reported to be edema (peripheral, per orbital and superficial). The other prevalent mild-moderate non hematologic ADRs were found to be fatigue, nausea, myalgia, abdominal pain, musculoskeletal pain, vomiting and skin rash.

Some of these events are similarly reported in other studies, e.g. fatigue, nausea, muscle cramp, abdominal pain, vomiting and skin rash. Our frequent severe non-hematologic ADRs (grade 3-4) were skin rash as well as Kantarjian et al. study.

Despite the higher frequency of grade 3-4 for hematologic events (thrombocytopenia and neutropenia) in other studies, hematologic ADRs were not recorded among our frequent severe symptoms.

**Effectiveness and Safety of imatinib in children**

We encountered with the lack of evidence in Iranian pediatric CML patients due to inclusion of only three studies which evaluated imatinib efficacy in children.
considered are limited. It can be associated with infrequent risk of CML incidence in children population. Two of our studies recruited patients who previously treated with other drugs such as HU. It could be due to enrolment of patients in these studies before FDA approval of imatinib pediatric use in 2003. In contrast with others, the number of females was more in these studies.

We faced with discrepancies in the responses of these studies. Hamidieh et al. responses were very lower compared to Bahoush et al. regarding CHR (58% vs. 93%, respectively) and CCyR (37% vs. 85.7%, respectively). Other studies on pediatrics reported range of CHR and CCyR 80-98% and 55-69%, respectively which are similar to Bahoush et al. results.

In addition, calculated mortality rate from the above-mentioned studies was lower than our results (14–21% vs. 2–4.5%); however, EFS and OS is compatible with our findings. These variations could be due to the stage of the disease that studies recruited their patients, genetic background, median participants’ age or imatinib therapy timing (1st or 2nd line therapy). Although Bahoush et al. stated that there are no differences in patients’ outcomes taking imatinib as first regimen or not, the sample size of their study was small (n=14, 2 groups of 7 patients). As we mentioned earlier, we are dealing with lack of evidence regarding Iranian pediatric imatinib efficacy which may alter our conclusion and lead to misconception.

Only one study reported detailed imatinib-induced adverse effects in pediatrics. Based on Bahoush et al. study, it seems that the total ADRs frequency in Iranian pediatric patients is high (93%).

In a review study by Suttorp et al., similar ADRs to Iranian pediatrics were reported. They stated edema, nausea, vomiting and musculoskeletal pain as common ADRs based on different pediatrics studies which are in accordance with Bahoush et al. study.

There is paucity of studies regarding imatinib efficacy and safety in pediatric CML patients. However, our studies showed acceptable responses by children to imatinib and have not induced any fatal events. Therefore, imatinib therapy was suggested for CML children who are faced with absence of fully matched sibling donors.

**Resistance characteristics**

Imatinib resistance can happen through different pathways such as BCR/ABL gene expression or routes that decrease available imatinib concentration. But majority of imatinib resistance is due to gene mutation. So far, 50 mutation regions and more than 70 particular mutations are recognized. It is suggested to evaluate the mutation in the case of imatinib resistance, prior to choosing the following treatment. Accordingly, we found about 70% studies which detected BCR/ABL point mutation after resistance occurrence. This can remark the high frequency and also the importance of this mechanism in imatinib-resistance occurrence. The mutation detection methods that were mostly applied by our studies are different types of PCR and direct sequencing. Kang et al. confirmed that ASO-RT-PCR method is more sensitive, simple and faster than direct sequencing or PCR-RFLP methods. They suggested ASO-RT-PCR method for routine BCR/ABL mutations screening and direct sequencing for confirmation in positive cases. Chahardouli et al. also detected mutation by ASO-RT-PCR in one of our included studies. They also reported STAT3 gene as an effective target in the treatment of resistant CML patients.

**Follow-up characteristics**

The ABL1 KD mutations frequency was calculated 18.6% (43/231 imatinib resistant patients) in four of our included studies. There are studies which reported more mutations in resistant patients like 32 mutations in 100 (32%) patients from Pakistan, 63% in Korean and 58% in Chinese patients. Among the reasons for these variations, we can point out 1) applying methods with different sensitivity such as direct sequencing and ASO-PCR, 2) inclusion of larger group of patients mostly in AP and BP, leading to
higher probability of detecting mutations and 3) the diversity of ethnic origins and genotypes. Treatment modification is implemented according to the patient’s condition and previous treatment. Our studies utilized high dose of imatinib 600-800 mg per day or second or third generation TKIs for resistant or mutated patients, as suggested \(^69,70\). Our included studies also followed the patients with modified regimen. These regimen modifications are supposed to be effective. It has been stated in the case of increasing imatinib dose, 50% of patients achieved the complete responses, and about 37.5% did not reflect any responses \(^67\). On the other hand, switching between the drugs within TKI group led to 41% complete cytogenetic response and 56% major cytogenetic response \(^71\). Although in our studies the authors did not make it clear that modifications outcomes were belonged to which groups (higher imatinib dose vs. next TKI generations), most of the patients could not achieve the proper responses or even lost former responses. These discrepancies may be because of recruited resistant patients in order to assess the patient’s outcomes from treatment modifications. Our studies mostly investigated imatinib resistant patients which were mutated and in all CP, AP and BP. While the other mentioned studies evaluated all resistant patients and only in CP \(^65,70\).

We found drug-binding site (T315I, etc.) and P-loop region as the most occurring mutations in resistant individuals. Kim et al. \(^46\) revealed the incidence of mutation in P-loop and drug-binding site as 44% and 27% of total mutations in all three phases, respectively and T315I as the most common mutation. Also, in our review article, mutations mostly happened in advanced phases (AP or BP). These findings are the same as Nicolini et al. study \(^72\). They also suggested that these sites mutations lead to an inferior OS. Therefore, mutation sites can be another reason for poor responses in these populations.

Generally, SIRT1 and MDR1 expression are higher in resistant patients than in sensitive patients to imatinib. BCR/ABL gene mutation almost happens in drug-binding site or P-loop regions. Escalating dose of imatinib or applying second or third generation TKIs have not led to proper responses in most patients in advanced phases or in whom which had particular mutations. So, it is suggested to perform the mutation screening prior choosing treatment strategy in the purpose of achieving optimal response and decreasing expenditures.

**CONCLUSION**

Although the included studies consisted of valuable information, this information was not beneficial in order to respond to some of our questions. Extracting data from these studies was difficult. Also, summing up their results was not convenient. These mainly were due to lack of quality in data reporting and the variation in evaluated characteristics. Some crucial characteristics were missing from one to another study, and they all did not cover equivalent information. Studies also varied in reporting denominators which makes it hard to track the whole situation. So, we need further studies with covering specific standard fields and identical reporting practices.

As we know for mapping the Iranian CML patients’ treatment, we cannot lay on abroad countries results because of the underlying conditions diversity. Hence, we need to design studies to evaluate if there is any correlation between underlying situations of individuals (e.g. patients own characteristics, disease characteristics, drug regimens before imatinib resistance, etc.) in resistance occurrence and responses to imatinib. Moreover, we need to assess the priorities in the afterward treatment. The accuracy and validity of the available data are doubtful due to their study designs. Our results mostly are qualitative, not investigative and analytical; as a result, we need further evaluation of drug modifications outcomes by conducting appropriate clinical trials with
Asiyeh Amouei, et al.

Different arms (e.g. different accelerated dose and switching to other TKI).

Conflicts Of Interest
The authors indicated no potential conflicts of interest.

REFERENCES
1. Mashkani B, Griffith R, Ashman L. Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants. Iran J Basic Med Sci. 2014;17(11):867-73.
2. Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007 Jun;18 Suppl 6:vii42-6.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-7.
4. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood; 2002. 99 (1): 319-25.
5. Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol. 2009; 21 Suppl 1:S43-6.
6. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002; 99 (9): 3472-5.
7. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27 (35): 6041-51.
8. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood; 2010. 116 (19): 3758-65.
9. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005. 183-7.
10. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362 (24): 2260-70.
11. Mitra D, Trask PC, Iyer S, et al. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012;95(3):263-73.
12. Henk HJ, Woloj M, Shapiro M, et al. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015;37(1):124-33.
13. Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol. 2012;86(1):1-12.
14. Zhu Y, Qian S-X. Clinical efficacy and safety of imatinib in the management of Ph+ chronic myeloid or acute lymphoblastic leukemia in Chinese patients. Onco Targets Ther. 2014;7:395-404.
15. Daroudi R, Mirzania M, Nikravanfard N, et al. Estimation of the prevalence and direct medical costs of chronic myeloid leukemia in the IR of Iran in the era of tyrosine kinase inhibitors. Asia Pac J Clin Oncol. 2017;13(5):e416-e422.
16. Mathews V. Generic imatinib: the real-deal or just a deal? Leuk Lymphoma. 2014;55(12):2678-80.
17. Navidi GR, Rezvan H, Samiei S, et al. A preliminary study on the effect of two therapeutic procedures on the expression of BCR-ABL gene in CML patients. Blood Journal. 2005; 2 (5): 151-6.
18. Yousefi P, Rostami S, Alizadeh Ghandfurosh N, et al. Study of STAT3 Expression in Different Phases of Patients with Chronic Myeloid Leukemia. Payavard. 2019; 13. (2): 101-9.
19. Moshfeghi K, Nazemzadeh N, Mehrzad V, et al. Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia. Adv Biomed Res. 2013; 217
20. Bahoush G, Albouyeh M, Vossough P. Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia. Int J Hematol Oncol Stem Cell Res. 2009;3 (3): 8-13.
21. Golabchifar A-A, Rezaee S, Ghavamzadeh A, et al. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Imatinib in Iranian CML Population

22. Mohajeri E, Kalantari-Khandani B, Pardakhty A, et al. Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients. Int J Hematol Oncol Stem Cell Res. 2015; 9 (4): 165-72.

23. Chahardouli B, Zaker F, Mousavi SA, et al. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Hematology. 2013. 18 (3): 158-62.

24. Chahardouli B, Zaker F, Mousavi SA, et al. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib. Hematology. 2013;18(6): 328-33.

25. Valizadeh N. Imatinib Induced Facial Skin Hyperpigmentation in a Case of Chronic Myelogenous Leukemia. Shiraz e med j (Online). 2011;12 (3):162-4.

26. Mozaheb Z, Javani M. Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia). Health. 2014; 6(6): 900-7.

27. Salimizand H, Amini S, Abdi M, et al. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumour Biol. 2016. 37 (1): 791-8.

28. Safaei A, Monabati A, Safavi M, et al. Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East. Blood Res. 2018; 53(1): 49-52.

29. Solali S, Kaviani S, Movassaghpour A, et al. Real-Time Polymerase Chain Reaction Testing for Quantitative Evaluation of hOCT1 and MDR1 Expression in Patients with Chronic Myeloid Leukemia Resistant to Imatinib. Lab Med.2013; 44(1): 13-9.

30. Rejali L, Poopak B, Hasanzad M, et al. Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance. Iran J Cancer Prev . 2015;8(3):e2334.

31. Razmkhah F, Razavi M, Zaker F, et al. Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia. Lab Med. 2010; 41 (9): 547-50.

32. Vatanmakanian M, Tavallaie M, Ghadami S. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function? Cell Commun Signal. 2019; 17 (1): 38.

33. Rostami G, Hamid M, Jalaiekho H. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia. Gene. 2017; 627: 202-6.

34. Vatanmakanian M, Tavallaie M, Ghadami S. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function? Cell Commun Signal. 2019; 17 (1): 38.

35. Payandeh M, Aeinfar M, Yari S, et al. Molecular monitoring of Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Asian Pac J Cancer Care. 2018; 4(1): 1-5.

36. Nekoohesh L, Rostami S, Nikbakht M, et al. Evaluation of molecular response to imatinib mesylate treatment in Iranian patients with chronic myeloid leukemia Evaluation of molecular response to generic Imatinib treatment in Iranian patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020; 20(1):e1-e10.

37. Jalaiekho H, Ahmadzadeh A, Toogeh G, et al. Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients. Arch Iran Med . 2011;14(6):378-80.

38. Rostami G, Hamid M, Yaran M, et al. Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia. J Hum Genet. 2015; 60 (5): 253-8.

39. Payandeh M, Sadeghi E, Sadeghi M. Non-hematological Adverse Events of Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). J Appl Pharm Sci. 2015; 5(2):87-90.

40. Hamidieh AA, Ansari S, Darbandi B, et al. The treatment of children suffering from chronic leukemia. Cancer Chemother Pharmacol . 2014;74(1):85-93.
myelogenous leukemia: a comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation. Pediatr Transplant . 2013;17(4):380-6.
41. Payandeh M, Sadeghi M, Sadeghi E. Treatment and survival in patients with chronic myeloid leukemia in a chronic phase in West Iran. Asian Pac J Cancer Prev. 2015; 16 (17): 7555-9.
42. Abbasian S, Ghotaslou A, Ghasemi A, et al. Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate. Iran J Blood Cancer. 2015; 7 (4): 184-90.
43. Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015; 94 Suppl 2. S241-7.
44. Breccia M, Tiribelli M, Alimena G. Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol. 2012; 84 (1): 93-100.
45. Hochhaus A, Kreil S, Corbin A5, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STIS71) therapy. Leukemia. 2002; 16 (11): 2190-6.
46. Kim SH, Kim D, Kim DW, et al. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol. 2009; 27 (4): 190-7.
47. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99 (6): 1928-37.
48. Druker BJ. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Eur J Cancer . 2002;38 Suppl 5:S70-6.
49. Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol . 2009;89(1):14-23.
50. Hochhaus A, O'brien S, Guilhot F, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med . 2006;355(23):2408-17.
51. Sánchez-Guijo FM, Durán S, Galende J, et al. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study. Leukemia Res. 2011; 35 (9): 1184-7.
52. Mealing S, Barcena L, Hawkins N, et al. The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp Hematol Oncol . 2013;2(1):5.
53. O'brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med . 2003;348(11):994-1004.
62. Muramatsu H, Takahashi Y, Sakaguchi H, et al. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. Int J Hematol. 2011;93(2):186-191.

63. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006; 20 (2): 187-92.

64. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009; 27 (3): 469-71.

65. Kang HY, Hwang JY, Kim SH, et al. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica. 2006; 91 (5): 659-62.

66. Yousefi P, Rostami S, Alizadeh Ghandfurossh N, et al. Study of STAT3 Expression in Different Phases of Patients with Chronic Myeloid Leukemia. Payavard. 2019; 13 (2): 101-9.

67. Iqbal Z, Aleem A, Iqbal M, et al. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One. 2013; 8 (2): e55717.

68. Qin Y, Chen S, Jiang B, et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol. 2011;90(1): 47-52.

69. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009; 4 (1): 3-10.

70. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101 (2): 473-5.

71. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011; 25 (1): 7-22.

72. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia. 2006; 20 (6): 1061-6.